'For the quarter ending March 2024, consolidated net sales (including other operating income) of Cipla has increased 7.39% to Rs 6163.24 crore compared to quarter ended March 2023.  Sales of Phamaceuticals segment has gone up 8.31% to Rs 5,996.38 crore (accounting for 96.57% of total sales).  Sales of New Ventures segment has gone down 8.91% to Rs 212.99 crore (accounting for 3.43% of total sales).  Inter-segment sales rose Rs 30.89 crore to Rs 46.13 crore.  

Profit before interest, tax and other unallocable items (PBIT) has jumped 32.71% to Rs 1,276.85 crore.  PBIT of Phamaceuticals segment rose 30.35% to Rs 1,322.45 crore (accounting for 103.57% of total PBIT).  PBIT of New Ventures segment rose 13.01% to Rs -45.60 crore (accounting for -3.57% of total PBIT).  

PBIT margin of Phamaceuticals segment rose from 18.33% to 22.05%.  PBIT margin of New Ventures segment rose from negative 22.42% t...

• 

  (22-Jan-2025)

  Dalmia Bharat

  PAT down 76.8% YoY to Rs 61 crore in Q3FY2025

• 

  (22-Jan-2025)

  Indiamart Intermesh

  Revenue up 16.05% YoY to Rs 354.3 crore in Q3FY2025

• 

  (22-Jan-2025)

  PNB Housing Finance

  AUM growth, asset quality and margin improves

• 

  (22-Jan-2025)

  L&T Finance

  Retail loan growth healthy at 23%, rural business segment shows high slippages